Back HCV Treatment

Simeprevir as Effective, Better Tolerated than Telaprevir in HCV Triple Therapy

The recently approved next-generation hepatitis C virus (HCV) protease inhibitor simeprevir (Olysio) produced sustained virological response rates similar to those of telaprevir (Incivek or Incivo) when combined with pegylated interferon and ribavirin, but with fewer side effects, researchers reported at theViral Hepatitis Congress taking place this week in Frankfurt.

alt

Read more: